Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
WCLD | -<0.01% | $377.26M | 0.45% |
IGE | 0.01% | $618.27M | 0.41% |
ESGU | -0.02% | $13.75B | 0.15% |
FTRI | -0.03% | $99.25M | 0.7% |
VONG | 0.03% | $29.36B | 0.07% |
PJUL | -0.03% | $1.12B | 0.79% |
PNQI | -0.03% | $772.45M | 0.6% |
JMOM | 0.03% | $1.57B | 0.12% |
CFA | 0.03% | $532.20M | 0.35% |
USPX | 0.04% | $1.27B | 0.03% |
VCLT | -0.04% | $9.70B | 0.04% |
IVW | 0.04% | $60.47B | 0.18% |
EJAN | 0.04% | $111.60M | 0.89% |
INCM | -0.05% | $711.59M | 0.38% |
IGLB | -0.05% | $2.33B | 0.04% |
VOE | 0.06% | $18.08B | 0.07% |
DFCF | 0.06% | $7.10B | 0.17% |
FEPI | -0.06% | $479.41M | 0.65% |
SCHI | -0.06% | $8.65B | 0.03% |
FFOG | -0.07% | $147.61M | 0.55% |
Current Value
$0.851 Year Return
Current Value
$0.851 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
INGR | -27.04% | $8.77B | +18.80% | 2.35% |
PGR | -25.72% | $146.19B | +17.73% | 1.98% |
VMEO | -21.34% | $663.92M | +6.61% | 0.00% |
K | -18.64% | $27.64B | +40.17% | 2.86% |
ALL | -18.35% | $51.55B | +20.14% | 1.98% |
XWDIX | -18.19% | - | - | 11.98% |
PFLT | -17.50% | - | - | 11.46% |
CNA | -16.65% | $11.89B | -2.30% | 4.11% |
GFL | -16.41% | $17.36B | +24.70% | 0.12% |
CCAP | -15.75% | - | - | 11.58% |
WTW | -15.66% | $30.72B | +18.26% | 1.17% |
PNNT | -15.56% | - | - | 13.42% |
CBOE | -15.36% | $24.55B | +38.09% | 1.08% |
PTMN | -15.14% | - | - | 18.34% |
HEI | -14.65% | $43.34B | +37.98% | 0.07% |
THG | -14.62% | $5.87B | +31.34% | 2.17% |
TRI | -14.56% | $90.81B | +22.05% | 0.86% |
SLF | -14.32% | $35.05B | +23.85% | 3.92% |
ACGL | -14.20% | $33.19B | -3.99% | 0.00% |
HEI.A | -14.18% | $33.67B | +35.55% | 0.09% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TTEK | <0.01% | $9.62B | -9.93% | 1.30% |
TEVA | <0.01% | $18.96B | -3.33% | 0.00% |
CPK | <0.01% | $2.88B | +13.54% | 2.11% |
WLY | 0.01% | $2.32B | -5.16% | 3.28% |
MX | 0.01% | $147.14M | -18.73% | 0.00% |
SOLV | 0.01% | $13.13B | +53.73% | 0.00% |
IAG | 0.01% | $4.00B | +64.30% | 0.00% |
MSCI | 0.02% | $44.93B | +17.63% | 1.17% |
SLE | 0.02% | $5.87M | -83.75% | 0.00% |
CPRX | -0.02% | $2.67B | +33.97% | 0.00% |
VNT | -0.02% | $5.71B | -2.74% | 0.26% |
DDOG | 0.03% | $47.48B | +8.10% | 0.00% |
NBR | 0.03% | $330.76M | -54.29% | 0.00% |
SE | 0.04% | $81.65B | +102.17% | 0.00% |
ADBE | 0.04% | $157.56B | -33.39% | 0.00% |
ABNB | -0.04% | $84.56B | -6.16% | 0.00% |
LB | 0.04% | $1.46B | +109.40% | 0.48% |
ITRN | -0.04% | $839.98M | +61.21% | 4.43% |
AGL | -0.04% | $956.23M | -62.44% | 0.00% |
POST | -0.04% | $6.00B | +0.75% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PBYI | 29.59% | $174.73M | +2.33% | 0.00% |
STTK | 27.15% | $37.09M | -80.88% | 0.00% |
MQ | 26.77% | $2.80B | +10.54% | 0.00% |
IBTA | 26.69% | $1.06B | -46.32% | 0.00% |
JELD | 25.23% | $396.64M | -67.18% | 0.00% |
ALLO | 25.02% | $275.60M | -52.99% | 0.00% |
KALV | 24.89% | $771.09M | +24.08% | 0.00% |
FATE | 24.84% | $132.97M | -65.88% | 0.00% |
AMTX | 24.80% | $184.93M | -6.44% | 0.00% |
COGT | 24.52% | $1.24B | +18.71% | 0.00% |
HDSN | 23.82% | $365.24M | -4.00% | 0.00% |
CVGI | 23.80% | $67.89M | -60.40% | 0.00% |
BTBT | 22.54% | $983.85M | -1.70% | 0.00% |
EVGO | 22.37% | $464.22M | +2.67% | 0.00% |
WOLF | 22.36% | $247.45M | -93.58% | 0.00% |
NATR | 22.22% | $288.95M | +4.06% | 0.00% |
HY | 21.51% | $754.78M | -37.62% | 3.34% |
DNA | 20.90% | $599.19M | -15.76% | 0.00% |
TKR | 20.88% | $5.50B | -4.14% | 1.75% |
CRSP | 20.61% | $5.10B | +3.85% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ARKG | 18.49% | $1.03B | 0.75% |
PBW | 16.28% | $294.50M | 0.65% |
IWMY | 14.69% | $120.43M | 1.02% |
GNOM | 14.52% | $46.47M | 0.5% |
ACES | 13.99% | $97.20M | 0.55% |
XHB | 13.88% | $1.42B | 0.35% |
IWC | 13.86% | $840.86M | 0.6% |
QCLN | 13.80% | $415.53M | 0.56% |
XBI | 13.76% | $4.81B | 0.35% |
XPH | 13.62% | $150.58M | 0.35% |
ETHE | 13.40% | $2.96B | 2.5% |
ITB | 13.33% | $2.43B | 0.39% |
SATO | 13.13% | $12.55M | 0.6% |
TAN | 12.74% | $677.56M | 0.71% |
PTH | 12.66% | $96.25M | 0.6% |
ICSH | 12.37% | $5.96B | 0.08% |
ETHW | 12.23% | $292.36M | 0% |
ETH | 12.17% | $1.40B | 0% |
FTSD | 12.11% | $233.11M | 0.25% |
EZET | 12.10% | $36.68M | 0% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
MNA | -19.52% | $233.72M | 0.77% |
CLOZ | -19.15% | $793.57M | 0.5% |
FLBL | -18.35% | $1.12B | 0.45% |
VRIG | -17.71% | $1.21B | 0.3% |
CSHI | -16.54% | $541.25M | 0.38% |
CLOA | -15.98% | $942.15M | 0.2% |
VPC | -14.30% | $54.97M | 9.86% |
THTA | -13.67% | $34.97M | 0.61% |
FLTR | -13.62% | $2.44B | 0.14% |
IAK | -13.41% | $789.50M | 0.39% |
BTAL | -13.33% | $315.93M | 1.43% |
FLOT | -13.31% | $8.90B | 0.15% |
EWS | -13.25% | $762.70M | 0.5% |
SRLN | -13.14% | $6.98B | 0.7% |
BKLN | -12.61% | $7.03B | 0.65% |
SEIX | -12.47% | $306.66M | 0.57% |
YLD | -12.05% | $319.43M | 0.39% |
FLRT | -12.01% | $525.35M | 0.6% |
PCEF | -11.92% | $818.28M | 3.07% |
TFLO | -11.77% | $6.74B | 0.15% |
Yahoo
– Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH® dispensed applicator units in Q2 2025 – – Company reports receipt of $8 million milestone payment from its Japanese development partner, Torii Pharmaceutical, for initiation of global Phase 3 program in common warts – WEST CHESTER, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications
Yahoo
– Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule – – Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of YCANTH® (TO-208 in Japan) for molluscum contagiosum in Japan; approval decision expected by the end of 2025 – – Torii to fund the first $40 million of out-of-pocket costs for the global study, representing approximately 90% of the current clinical budget – – Common warts affec
Yahoo
Verrica Pharmaceuticals Inc. ( NASDAQ:VRCA ) is possibly approaching a major achievement in its business, so we would...
Yahoo
WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in New York City. Jefferies Global Healthcare Conference, June 3-5, 2025Event details:Date: We
Yahoo
Q1 2025 Verrica Pharmaceuticals Inc Earnings Call
Yahoo
Verrica Pharmaceuticals Inc (VRCA) reports robust revenue growth and strategic advancements, despite facing a net loss and funding uncertainties.